Francesco Zaja

List of Publications by Citations

Source: https://exaly.com/author-pdf/9094131/francesco-zaja-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

149 papers	7,697 citations	46 h-index	86 g-index
152 ext. papers	8,999 ext. citations	5.7 avg, IF	5 L-index

#	Paper	IF	Citations
149	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. *Lancet, The*, **2009**, 374, 1512-20	40	478
148	Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. *Blood*, **2004**, 103, 2474-9	2.2	460
147	Efficacy and safety of rituximab in type II mixed cryoglobulinemia. *Blood*, **2003**, 101, 3827-34	2.2	392
146	ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. *New England Journal of Medicine*, **2011**, 365, 203-12	59.2	282
145	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. *Blood Advances*, **2019**, 3, 3780-3817	7.8	267
144	Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. *Blood*, **2007**, 110, 2316-23	2.2	260
143	Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. *Journal of Clinical Oncology*, **1999**, 17, 1254	2.2	229
142	Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. *Arthritis and Rheumatism*, **2002**, 46, 2029-33		219
141	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. *New England Journal of Medicine*, **2015**, 373, 1733-47	59.2	215
140	Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. *Blood*, **2010**, 115, 2755-62	2.2	199
139	The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. *Blood*, **2009**, 114, 3167-72	2.2	169
138	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. *Blood*, **2015**, 126, 1921-4	2.2	167
137	Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. *Blood*, **2002**, 99, 856-62	2.2	147
136	Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. *Journal of Clinical Oncology*, **2013**, 31, 1442-9	2.2	137
135	Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. *American Journal of Hematology*, **2018**, 93, 921-930	7.1	131
134	Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. *Cancer*, **2005**, 104, 2437-41	6.4	129
133	Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. *Journal of Clinical Oncology*, **2012**, 30, 2988-94	2.2	125

132	Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. *Journal of Clinical Oncology* , **2004**, 22, 2654-61	2.2	123
131	The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. *Experimental Hematology*, **2006**, 34, 389-96	3.1	121
130	Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. *Blood*, **2016**, 128, 2527-2532	2.2	115
129	Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. *Journal of Clinical Oncology*, **2016**, 34, 1376-85	2.2	101
128	Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. *European Journal of Cancer*, **2004**, 40, 1682-8	7.5	99
127	Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. *Blood*, **2009**, 114, 4696-702	2.2	95
126	Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. *Blood*, **2013**, 121, 4902-5	2.2	94
125	Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. *Blood*, **2012**, 119, 3691-7	2.2	93
124	Low-dose rituximab in adult patients with primary immune thrombocytopenia. *European Journal of Haematology*, **2010**, 85, 329-34	3.8	88
123	Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. *Blood*, **2005**, 105, 3428-33	2.2	88
122	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. *MAbs*, **2013**, 5, 826-37	6.6	83
121	B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. *Haematologica*, **2002**, 87, 189-95	6.6	83
120	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. *Lancet Infectious Diseases, The*, **2019**, 19, 988-1000	25.5	82
119	Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. *Cancer*, **2012**, 118, 434-43	6.4	77
118	Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. *Haematologica*, **2013**, 98, 875-80	6.6	76
117	Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. *Haematologica*, **2008**, 93, 930-3	6.6	74
116	Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. *Leukemia and Lymphoma*, **2003**, 44, 1951-5	1.9	74
115	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. *Lancet Oncology, The*, **2017**, 18, 1076-1088	21.7	72

114	Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. *Therapeutic Drug Monitoring*, **2005**, 27, 785-92	3.2	72
113	Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. *Blood*, **2013**, 122, 3759-66	2.2	63
112	B-cell compartment as the selective target for the treatment of immune thrombocytopenias. *Haematologica*, **2003**, 88, 538-46	6.6	63
111	Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. *Haematologica*, **2012**, 97, 416-22	6.6	58
110	Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters. *Blood*, **2012**, 119, 2310-3	2.2	57
109	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. *Haematologica*, **2013**, 98, 1232-6	6.6	57
108	Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. *European Journal of Haematology*, **2008**, 81, 165-9	3.8	54
107	Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. *Oncologist*, **2006**, 11, 285-91	5.7	51
106	Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. *Journal of Clinical Oncology*, **2013**, 31, 3351-9	2.2	48
105	Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. *Clinical and Developmental Immunology*, **2012**, 2012, 638185		47
104	Rituximab for the treatment of type II mixed cryoglobulinemia. *Arthritis and Rheumatism*, **2002**, 46, 2252-4; author reply 2254-5		47
103	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. *Blood*, **2019**, 134, 1132-1143	2.2	46
102	Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. *Experimental Hematology*, **2006**, 34, 571-2	3.1	44
101	Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. *Blood*, **2019**, 133, 919-926	2.2	44
100	Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. *European Journal of Haematology*, **2017**, 98, 371-377	3.8	42
99	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. *Journal of Experimental Medicine*, **2018**, 215, 681-697	16.6	41
98	Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. *Leukemia and Lymphoma*, **2015**, 56, 2637-42	1.9	41
97	Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. *American Journal of Hematology*, **2012**, 87, 886-9	7.1	40

96	Incidence and diagnosis of EDTA-dependent pseudothrombocytopenia in a consecutive outpatient population referred for isolated thrombocytopenia. *Vox Sanguinis*, **1995**, 68, 35-9	3.1	40
95	Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment. *British Journal of Haematology*, **2001**, 112, 370-2	4.5	38
94	Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. *European Journal of Haematology*, **2013**, 91, 546-51	3.8	37
93	CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. *Blood*, **2013**, 122, 3317-21	2.2	36
92	Biological and clinical implications of mutations in chronic lymphocytic leukemia. *Haematologica*, **2020**, 105, 448-456	6.6	35
91	Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. *Blood*, **2018**, 132, 547-550	2.2	34
90	MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. *Neurology*, **2014**, 82, 1370-3	6.5	33
89	Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). *Annals of Hematology*, **2012**, 91, 1013-22	3	33
88	BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine. *Leukemia and Lymphoma*, **1998**, 28, 567-72	1.9	28
87	Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. *New England Journal of Medicine*, **2021**, 384, 1810-1823	59.2	28
86	Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?. *Haematologica*, **2019**, 104, 1124-1135	6.6	27
85	Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. *Oncologist*, **2011**, 16, 336-41	5.7	27
84	Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. *Leukemia and Lymphoma*, **2011**, 52, 2226-36	1.9	27
83	Endogenous endophthalmitis following disseminated fungemia due to Fusarium solani in a patient with acute myeloid leukemia. *European Journal of Haematology*, **2002**, 68, 314-7	3.8	27
82	Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. *American Journal of Hematology*, **2012**, 87, 321-3	7.1	25
81	Bendamustine salvage therapy for T cell neoplasms. *Annals of Hematology*, **2013**, 92, 1249-54	3	25
80	Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study. *American Journal of Hematology*, **2016**, 91, E293-5	7.1	25
79	Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. *Lancet Haematology,the*, **2017**, 4, e137-e146	14.6	22

78	CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?. *American Journal of Hematology*, **2017**, 92, E1-E2	7.1	22
77	Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study. *Magnetic Resonance Materials in Physics, Biology, and Medicine*, **1996**, 4, 213-24	2.8	22
76	Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. *Hematological Oncology*, **2018**, 36, 68-75	1.3	20
75	Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers. *American Journal of Hematology*, **2018**, 93, 58-64	7.1	19
74	Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin lymphoma: evidence from a multicenter, retrospective study. *Annals of Hematology*, **2016**, 95, 1107-14	3	19
73	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. *Blood*, **2020**, 135, 1244-1254	2.2	18
72	The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single center. *Leukemia and Lymphoma*, **1999**, 35, 159-69	1.9	18
71	Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. *Haematologica*, **2017**, 102, e203-e206	6.6	17
70	MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients. *Haematologica*, **2019**, 104, e25-e28	6.6	17
69	Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. *Leukemia and Lymphoma*, **2015**, 56, 1671-6	1.9	17
68	Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT). *Biology of Blood and Marrow Transplantation*, **2019**, 25, 2474-2481	4.7	16
67	Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. *OncoTargets and Therapy*, **2014**, 7, 865-72	4.4	16
66	Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study. *Haematologica*, **2021**, 106, 622-625	6.6	16
65	NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. *British Journal of Haematology*, **2018**, 182, 597-602	4.5	15
64	Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha. *British Journal of Haematology*, **1996**, 94, 300-5	4.5	15
63	Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. *Leukemia*, **2020**, 34, 1462-1466	10.7	15
62	Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. *Leukemia and Lymphoma*, **2018**, 59, 1814-1828	1.9	15
61	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. *Journal of Hematology and Oncology*, **2013**, 6, 83	22.4	14

60	Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice. *American Journal of Hematology*, **2013**, 88, 955-60	7.1	14
59	Hepatitis C virus infection (and additional neoplasms) among marginal zone lymphomas. *British Journal of Haematology*, **1997**, 96, 427-8	4.5	14
58	The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. *Oncotarget*, **2015**, 6, 19102-17	3.3	13
57	Mutations in the 3Quntranslated region of are associated with low CD20 expression levels chronic lymphocytic leukemia. *Haematologica*, **2017**, 102, e305-e309	6.6	11
56	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. *Leukemia*, **2019**, 33, 2111-2115	10.7	10
55	Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)--positive anaplastic large cell lymphoma in adults. *Leukemia and Lymphoma*, **1997**, 24, 369-77	1.9	10
54	A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1814-1822	4.7	10
53	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. *British Journal of Haematology*, **2018**, 182, 807-815	4.5	8
52	Mutational status of is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. *Haematologica*, **2017**, 102, e443-e446	6.6	8
51	Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial. *Leukemia and Lymphoma*, **2017**, 58, 1640-1647	1.9	8
50	Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. *Leukemia and Lymphoma*, **2014**, 55, 988-98	1.9	8
49	Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant. *American Journal of Hematology*, **2011**, 86, 790-2	7.1	8
48	Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. *American Journal of Hematology*, **2019**, 94, 628-634	7.1	7
47	Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma. *American Journal of Hematology*, **2015**, 90, E73	7.1	7
46	Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia. *Hematological Oncology*, **2019**, 37, 117-128	1.3	7
45	Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. *British Journal of Haematology*, **2021**, 193, 386-396	4.5	7
44	Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia. *British Journal of Haematology*, **2017**, 176, 258-267	4.5	6
43	Clinical features and outcome of multiple myeloma arising from the transformation of a monoclonal gammapathy of undetermined significance. *Leukemia and Lymphoma*, **1999**, 34, 591-6	1.9	6

42	Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas. *Leukemia and Lymphoma*, **1995**, 16, 465-70	1.9	6
41	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. *Haematologica*, **2020**, 105, 1613-1620	6.6	6
40	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. *Leukemia and Lymphoma*, **2018**, 59, 2904-2910	1.9	5
39	Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review. *Journal of NeuroVirology*, **2017**, 23, 908-912	3.9	5
38	No evidences for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy. *Haematologica*, **2008**, 93, 795-6	6.6	5
37	More on False Thrombocytopenias: EDTA-Dependent Pseudothrombocytopenia Associated with a Congenital Platelet Release Defect. *Vox Sanguinis*, **1996**, 71, 27-29	3.1	5
36	Management of immune thrombocytopenia in elderly patients. *European Journal of Internal Medicine*, **2018**, 58, 70-76	3.9	5
35	The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study. *Leukemia and Lymphoma*, **2017**, 58, 226-229	1.9	4
34	Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation. *Hematological Oncology*, **2020**, 38, 257-265	1.3	4
33	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. *Leukemia Research*, **2014**, 38, 198-203	2.7	4
32	Two cases of concomitant diffuse large B-cell lymphoma and myelodysplastic syndrome. *American Journal of Hematology*, **2014**, 89, 1011-3	7.1	4
31	Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. *Leukemia and Lymphoma*, **2009**, 50, 1824-9	1.9	4
30	SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. *Haematologica*, **2021**, 106, 3125-3135	6.6	4
29	Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum. *Blood Advances*, **2020**, 4, 1013-1019	7.8	4
28	Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. *Blood*, **2021**, 138, 571-583	2.2	4
27	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. *Expert Opinion on Biological Therapy*, **2017**, 17, 821-836	5.4	3
26	More on false thrombocytopenias: EDTA-dependent pseudothrombocytopenia associated with a congenital platelet release defect. *Vox Sanguinis*, **1996**, 71, 27-9	3.1	3
25	Long Term Follow up Analysis Following Front Line Therapy with Dexamethasone or Dexamethasone Plus Rituximab in Adults with Primary Immune Thrombocytopenia.. *Blood*, **2009**, 114, 2415-2415	2.2	3

24	Salvage Treatment with Lenalidomide and Dexamethasone In Patients with Relapsed Refractory Mantle Cell Lymphoma: Clinical Results and Modifications of Angiogenic Biomarkers. *Blood*, **2010**, 116, 966-966	2.2	3
23	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice, the Lenamant Study. *Blood*, **2015**, 126, 3946-3946	2.2	3
22	Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. *Clinical Cancer Research*, **2021**, 27, 5566-5575	12.9	3
21	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. *Haematologica*, **2019**, 104, e410-e414	6.6	2
20	HSV-1 cutaneous infection in a patient with Hodgkin lymphoma treated with brentuximab vedotin. *Journal of Chemotherapy*, **2013**, 25, 381-2	2.3	2
19	Trisomy 8 in chronic lymphocytic leukemia: a report of two cases. *Cancer Genetics and Cytogenetics*, **2007**, 175, 175-6		2
18	Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study). *Blood*, **2018**, 132, 1135-1135	2.2	2
17	A Prospective Randomized Study of Rituximab and Dexamethasone vs Dexamethasone Alone in ITP.. *Blood*, **2007**, 110, 567-567	2.2	2
16	Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries. *Leukemia and Lymphoma*, **2018**, 59, 2113-2120	1.9	1
15	Surgical staging in Hodgkin disease: the role of laparoscopic splenectomy. *European Journal of Haematology*, **1996**, 57, 114-6	3.8	1
14	Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.. *Leukemia Research*, **2022**, 114, 106803	2.7	1
13	Low-Dose Rituximab in Idiopathic Autoimmune Hemolytic Anemia.. *Blood*, **2009**, 114, 4027-4027	2.2	1
12	Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study. *Blood*, **2015**, 126, 2946-2946	2.2	1
11	Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations. *Therapeutic Advances in Hematology*, **2021**, 12, 20406207211048361	5.7	1
10	Immune thrombocytopenia. *Expert Review of Hematology*, **2021**, 1-13	2.8	1
9	Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. *Blood Advances*, **2021**, 5, 4504-4514	7.8	1
8	Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi.. *Frontiers in Oncology*, **2021**, 11, 789891	5.3	0
7	High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). *Haematologica*, **2020**, 105, 2671-2674	6.6	

6	The Role of Rituximab in the Therapy of Mixed Cryoglobulinemia **2012**, 297-305	
5	Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia. *Leukemia and Lymphoma*, **2002**, 43, 1893-4	1.9
4	ITP World Impact Survey (I-WISh) 2.0: Further Exploration of the Impact of ITP on Patients. *Blood*, **2020**, 136, 2-3	2.2
3	A Phase II Study to Assess the Sustained Response Off Treatment in Patients with ITP Receiving Eltrombopag, Who Had a Previous Insufficient Response to Corticosteroids (TAPER): A Recruitment Update. *Blood*, **2020**, 136, 37-38	2.2
2	Lack of Prognostic Significance of the Conventional and Novel Prognostic Markers in Trisomy 12 Chronic Lymphocytic Leukemia (CLL). *Blood*, **2016**, 128, 4354-4354	2.2
1	Interim Analysis Of An Ongoing PHASE II Trial Assessing Safety and Efficacy Of Lenalidomide Maintenance In Patients With Chemosensitive Relapse Of Diffuse Large B-CELL Lymphoma (DLBCL). *Blood*, **2013**, 122, 3055-3055	2.2